Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

versus pemetrexed plus platin
nivolumab plus SoC
CheckMate 227 (NC vs C ; PDL1<1%), 2018
  NCT02477826
RCTmNSCLC - L1 - PDL1 negativenivolumab plus pemetrexed plus platineplatinum based chemotherapy (pemetrexed plus platine)patients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and TMB > 10mut/Mb177 / 186some concern
conclusif
  • demonstrated 27 % decrease in progression or deaths (PFS) (PE)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
nivolumab alone
CheckMate 026 (PDL1>5%), 2016
  NCT02041533
RCTmNSCLC - L1 - PDL1 positiveNivolumabplatinum-based chemotherapypatients previously untreated had histologically confirmed squamous-cell or nonsquamous stage IV or recurrent NSCLC PD-L1 at >1%211 / 212some concern
inconclusive
  • inconclusive 15 % increase in progression or deaths (PFS) (PE)
CheckMate 026 (PDL1>1%), 2016
  NCT02041533
RCTmNSCLC - L1 - PDL1 positiveNivolumabplatinium doublet chemotherapypatients previously untreated had histologically confirmed squamous-cell or nonsquamous stage IV or recurrent NSCLC with PD-L1 >1%271 / 270some concern
inconclusive
    no statistically significant result